The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has provided positive opinion for the Janssen Pharmaceutical Companies of Johnson & Johnson’s CARVYKTI (cilta-cel) for earlier stage of relapsed and refractory multiple myeloma (RRMM) treatment.
The US Food and Drug Administration (FDA) has granted fast track designation to Artiva Biotherapeutics’ AlloNK, in combination with rituximab or obinutuzumab, for the treatment of lupus nephritis (LN).
UK-based biotechnology company IsomAb has secured £7.5m (approximately $9.4m) in a seed funding round to expedite the development of its lead candidate targeting peripheral arterial disease.
Everest Medicines has announced plans to terminate its partnership and licence agreements with Providence Therapeutics for the development of products using its mRNA platform.
The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation for Otsuka Pharmaceutical's sibeprenlimab, an investigational drug for treating immunoglobulin A nephropathy (IgAN; Berger’s disease).
Atara Biotherapeutics has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) for its chimeric antigen receptor (CAR) T-cell therapy ATA3219 for treating lupus nephritis.
Clinical-stage biotechnology company ProfoundBio has secured $112m in a Series B financing round to advance its clinical-stage antibody-drug conjugate (ADC) pipeline for cancer treatment.
Precision BioSciences has received upfront cash payment and equity investment totalling $17.5m from TG Therapeutics for an exclusive licence to develop Azercabtagene Zapreleucel (azer-cel).
Aizon, an artificial intelligence (AI) Software as a Service (SaaS) provider for pharmaceutical manufacturing operations, has secured $20m in Series C funding to expedite its development pipeline.
Contract development and manufacturing organization (CDMO) Samsung Biologics has entered into a strategic partnership with LegoChem Biosciences to advance antibody-drug conjugate (ADC) programmes aimed at treating solid tumours.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.